These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16740761

  • 1. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [Abstract] [Full Text] [Related]

  • 2. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res; 2008 Apr 01; 14(7):2088-94. PubMed ID: 18381949
    [Abstract] [Full Text] [Related]

  • 3. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
    Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S.
    Cancer; 2011 Feb 15; 117(4):809-18. PubMed ID: 20922800
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A.
    J Thorac Oncol; 2007 Apr 15; 2(4):299-305. PubMed ID: 17409801
    [Abstract] [Full Text] [Related]

  • 5. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD.
    Clin Cancer Res; 2005 May 01; 11(9):3342-8. PubMed ID: 15867233
    [Abstract] [Full Text] [Related]

  • 6. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
    Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH.
    Clin Cancer Res; 2005 Sep 15; 11(18):6634-40. PubMed ID: 16166442
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.
    Lung Cancer; 2014 May 15; 84(2):161-7. PubMed ID: 24636848
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
    Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H.
    Clin Cancer Res; 2009 Mar 15; 15(6):2158-65. PubMed ID: 19276291
    [Abstract] [Full Text] [Related]

  • 9. Bexarotene and erlotinib for aerodigestive tract cancer.
    Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.
    J Clin Oncol; 2005 Dec 01; 23(34):8757-64. PubMed ID: 16314636
    [Abstract] [Full Text] [Related]

  • 10. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
    Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM.
    J Thorac Oncol; 2008 Feb 01; 3(2):117-24. PubMed ID: 18303430
    [Abstract] [Full Text] [Related]

  • 11. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N.
    J Thorac Oncol; 2008 Apr 01; 3(4):374-9. PubMed ID: 18379355
    [Abstract] [Full Text] [Related]

  • 12. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
    Nugent FW, Mertens WC, Graziano S, Levitan N, Collea R, Gajra A, Marshall J, McCann J.
    Lung Cancer; 2005 May 01; 48(2):267-73. PubMed ID: 15829328
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS.
    Cancer; 2012 Dec 01; 118(23):5903-11. PubMed ID: 22605616
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
    Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM.
    Cancer; 2015 Sep 15; 121(18):3298-306. PubMed ID: 26033830
    [Abstract] [Full Text] [Related]

  • 15. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.
    J Clin Oncol; 2004 Mar 01; 22(5):785-94. PubMed ID: 14990633
    [Abstract] [Full Text] [Related]

  • 16. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A.
    J Clin Oncol; 2005 Apr 10; 23(11):2544-55. PubMed ID: 15753462
    [Abstract] [Full Text] [Related]

  • 17. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
    Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, Dunne M, Miller VA.
    Cancer; 2006 Sep 01; 107(5):1034-41. PubMed ID: 16878326
    [Abstract] [Full Text] [Related]

  • 18. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
    Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK.
    Clin Cancer Res; 2006 Dec 15; 12(24):7406-13. PubMed ID: 17189413
    [Abstract] [Full Text] [Related]

  • 19. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, Saito R, Dobashi K, Mori M.
    Lung Cancer; 2007 Jun 15; 56(3):383-9. PubMed ID: 17368623
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA.
    Lung Cancer; 2012 Oct 15; 78(1):57-62. PubMed ID: 22809813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.